Treatment administration
| Variable . | Ixazomib . | Cyclophosphamide . | Dexamethasone . |
|---|---|---|---|
| No. of cycles administered | 255 | 219 | 219 |
| Median dose per cycle | 12 | 2000 | 160 |
| Range | 0-12 | 0-2000 | 0-160 |
| No. of patients with adjustments | 5 | 3 | 10 |
| Total reductions | 6 | 4 | 12 |
| Reasons for adjustments | |||
| Investigations | 1 | 0 | 0 |
| Gastrointestinal disorders | 0 | 0 | 3 |
| General disorders and administration site conditions | 0 | 0 | 4 |
| Metabolism/nutrition disorders | 0 | 0 | 1 |
| Musculoskeletal-connective tissue disorders | 0 | 0 | 1 |
| Nervous system disorders | 3 | 0 | 0 |
| Per protocol | 1 | 1 | 0 |
| Other | 1 | 3 | 3 |
| Variable . | Ixazomib . | Cyclophosphamide . | Dexamethasone . |
|---|---|---|---|
| No. of cycles administered | 255 | 219 | 219 |
| Median dose per cycle | 12 | 2000 | 160 |
| Range | 0-12 | 0-2000 | 0-160 |
| No. of patients with adjustments | 5 | 3 | 10 |
| Total reductions | 6 | 4 | 12 |
| Reasons for adjustments | |||
| Investigations | 1 | 0 | 0 |
| Gastrointestinal disorders | 0 | 0 | 3 |
| General disorders and administration site conditions | 0 | 0 | 4 |
| Metabolism/nutrition disorders | 0 | 0 | 1 |
| Musculoskeletal-connective tissue disorders | 0 | 0 | 1 |
| Nervous system disorders | 3 | 0 | 0 |
| Per protocol | 1 | 1 | 0 |
| Other | 1 | 3 | 3 |